Tuesday, February 6, 2018
|Continuing education credits available until:|
|Tuesday, February 5, 2019|
Marty Sellers, MD, MPH - Moderator
Associate Medical Director
LifeLink of Georgia
Davis S Goldberg, MD, MSCE - Speaker
Assistant Professor of Medicine, Medical Director for Living Donor Liver Transplantation
University of Pennsylvania
Click here for Speaker Biography
Hundreds of high-quality organs from HCV-positive donors are ruled out or discarded annually. Transplanting these organs into HCV-negative recipients is a feasible way to optimize organ utilization, as anti-HCV therapy is now effective in the post-transplant setting. Recent data confirm the safety of transplanting HCV-positive organs into HCV-negative recipients, who then undergo anti-HCV therapy; moreover, reported transplant outcomes are excellent. Experience has been gained in both abdominal and thoracic transplant recipients. These data will be presented in detail by Dr. David Goldberg, a national thought-leader on this topic and one of the pioneers of this strategy.
Members of the donation and transplantation community serving diverse populations to include administrators, coordinators, physicians, nurses, surgeons, managers, quality improvement specialists, social workers, and other donation and transplantation center professionals and their colleagues.
At the end of the webinar, participants should be able to:
- Identify the number of organs discarded annually due to HCV infection in deceased donors.
- Discuss the effectiveness of anti-HCV therapy in the post-transplant setting..
- Summarize outcomes associated with transplanting HCV-positive organs into HCV-negative recipients.
Click here for more information on CE Credits